Fetal aneuploidy detection by sequencing

Patent metadata

Field	Value
Publication number	US-2024141424-A1
Application number	US-202318310098-A
Country	US
Kind code	A1
Filing date	May 1, 2023
Priority date	Jun 14, 2006
Publication date	May 2, 2024
Grant date	—

Abstract

The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions.

First claim

1 - 52 . (canceled)

53 . A method for detecting signal intensities on a microarray, the method comprising:
a. enriching a maternal blood sample for fetal genomic DNA (gDNA) to produce an enriched sample comprising fetal gDNA and maternal gDNA and having an increased concentration of fetal gDNA relative to maternal gDNA as compared to a concentration of fetal gDNA in the maternal blood sample before enrichment; b. hybridizing probes to a plurality of loci in the gDNA on at least two different chromosomes, wherein the plurality of loci comprise single nucleotide polymorphism (SNP) sites of a first chromosome selected from the group consisting of chromosomes 13, 18, 21, X, and Y in the enriched sample; c. ligating the hybridized probes at each locus to each other to create an amplification template specific to each locus; d. amplifying the amplification template specific to each locus to create amplification products; e. hybridizing the amplification products to probes on a microarray; and f. detecting signal intensities of the amplification products hybridized to probes on the microarray.

54 . The method of claim 53 , wherein the maternal blood sample is from a pregnant woman within a first or second trimester.

55 . The method of claim 53 , further comprising attaching the gDNA to a solid support.

56 . The method of claim 55 , wherein the solid support comprises a paramagnetic particle.

57 . The method of claim 55 , wherein the solid support comprises streptavidin.

58 . The method of claim 55 , wherein the gDNA is biotin-labeled.

59 . The method of claim 53 , wherein three oligonucleotide probes are provided for each locus.

60 . The method of claim 53 , wherein the gDNA is attached to a particle and the ligation occurs while the gDNA is attached to the particle, thereby forming an amplification template annealed to the gDNA attached to the particle.

61 . The method of claim 60 , further comprising releasing the amplification template from the gDNA attached to the particle.

62 . The method of claim 53 , wherein the amplification template comprises universal PCR primer sites and the amplification comprises hybridization of universal primers to the universal PCR primer sites.

63 . The method of claim 53 , wherein the microarray is a DNA microarray.

64 . A method for detecting signal intensities on a microarray, the method comprising:
a. enriching a maternal blood sample for fetal cells to produce an enriched sample comprising fetal and maternal cells and having an increased concentration of fetal cells relative to maternal cells compared to the concentration of fetal cells in the maternal blood sample before enrichment, and lysing the cells in the enriched sample to obtain genomic DNA (gDNA); b. hybridizing probes to a plurality of loci in the gDNA on at least two different chromosomes, wherein the plurality of loci comprises single nucleotide polymorphism (SNP) sites of a first chromosome selected from the group consisting of chromosomes 13, 18, 21, X, and Y in the enriched sample; c. ligating the hybridized probes at each locus to each other to create an amplification template specific to each locus; d. amplifying the amplification template specific to each locus to create amplification products; e. hybridizing the amplification products to probes on a microarray; and f. detecting signal intensities of the amplification products hybridized to probes on the microarray.

65 . The method of claim 64 , wherein the maternal blood sample is from a pregnant woman within a first or second trimester.

66 . The method of claim 64 , further comprising attaching the gDNA to a solid support.

67 . The method of claim 66 , wherein the solid support comprises a paramagnetic particle.

68 . The method of claim 66 , wherein the solid support comprises streptavidin.

69 . The method of claim 66 , wherein the gDNA is biotin-labeled.

70 . The method of claim 64 , wherein three oligonucleotide probes are provided for each locus.

71 . The method of claim 64 , wherein the gDNA is attached to a particle and the ligation occurs while the gDNA is attached to the particle, thereby forming an amplification template annealed to the gDNA attached to the particle.

72 . The method of claim 71 , further comprising releasing the amplification template from the gDNA attached to the particle.

73 . The method of claim 64 , wherein the amplification template comprises universal PCR primer sites and the amplification comprises hybridization of universal primers to the universal PCR primer sites.

74 . The method of claim 64 , wherein the microarray is a DNA microarray.

Assignees

• Verinata Health Inc
• Massachusetts Gen Hospital
• Gpb Scientific Llc

Inventors

• Stoughton Roland
• Kapur Ravi
• Cohen Barb Ariel
• Toner Mehmet

Classifications

• C12Q1/6874 Primary

  involving nucleic acid arrays, e.g. sequencing by hybridisation · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title